You are here

Article Text

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma
  1. J. J. Jobsen*,
  2. M.L.M. Lybeert†,
  3. E. M. Van Der Steen-Banasik‡,
  4. A. Slot§,
  5. J. Van Der Palen‖,
  6. L. N. Ten Cate,
  7. A. Scholten#,
  8. V. Coen**,
  9. E. M.J. Schutter†,‡ and
  10. S. Siesling†,‡
  1. * Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands;
  2. † Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands;
  3. ‡ Radiotherapeutic Institute Arnhem, Arnhem, The Netherlands;
  4. § Radiotherapy Institute Friesland, Leeuwarden, The Netherlands;
  5. ‖ Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands;
  6. Laboratorium Pathologie Oost Nederland, Enschede, The Netherlands;
  7. # Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands;
  8. ** Zeeuws Radiotherapy Institute, Vlissingen, The Netherlands;
  9. †† Departments of Obstetrics and Gynaecology, Medisch Spectrum Twente, Enschede, The Netherlands;
  10. ‡‡ Comprehensive Cancer Centre Stedendriehoek Twente, Enschede, The Netherlands
  1. Address correspondence and reprint requests to: Jan J. Jobsen, MD, Department of Radiation Oncology, Medisch Spectrum Twente, Haaksbergerstraat 55, 7513 ER Enschede, The Netherlands. Email: j.jobsen{at}ziekenhuis-mst.nl

Abstract

The aim of this study was to report outcome data and prognostic factors from a large cohort of pathologic stage II endometrioid type endometrial carcinoma. One hundred forty-two stage IIA–B patients were included. A central histopathologic review was performed. Follow-up ranged from 2 to 217 months with a median of 61 months. End points of the study were local and locoregional recurrence rates, distant metastasis–free survival (DMFS), disease-free survival (DFS), and disease-specific survival (DSS). The local failure rate was 5.1% for stage IIA patients and 10.8% for stage IIB patients. Grade was the only significant prognostic factor for local failure. With respect to DMFS, DFS, and DSS, grade 3 showed to be the most prominent prognostic factor in multivariate analyses. Lymphvascular space involvement combined with grades 3 and 2 and myometrial invasion greater than 0.5 also showed to be significant for DMFS and DFS. Our study showed grade 3 to be the most important single independent predictive factor for locoregional and distant recurrences in endometrial carcinoma stage II

  • endometrial carcinoma
  • outcome
  • prognostic factors
  • stage II

http://dx.doi.org/10.1111/j.1525-1438.2007.01142.x

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.